Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

Core Insights - Moderna announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2 [1] - The vaccine demonstrated a greater than 16-fold increase in LP.8.1-neutralizing antibodies across age groups [1] Company Summary - The ongoing Phase 4 clinical trial evaluates the safety, tolerability, and immunogenicity of the 2025-2026 formula of mNEXSPIKE [1] - The vaccine showed strong immune responses against the top circulating COVID-19 strains [1] Age Group Analysis - The data indicates a significant increase in neutralizing antibodies in individuals aged 12 to 64 with underlying conditions and all adults aged 65 and older [1]